Abstracts tagged "ANCA"

Abstract Number: 2726 • 2018 ACR/ARHP Annual Meeting
Severe Infections in Systemic Necrotizing Vasculitis: Incidence and Risk Factors
Claudia Elizabeth Pena¹, Ana Carolina Costi², Lucila Garcia³, Mariana Pera⁴ and Mercedes Garcia¹, ¹Rheumatology, HIGA General San Martin La Plata, La Plata, Argentina, ²Rheumatology Section, HIGA General San Martin La Plata, La Plata, Argentina, ³HIGA General San Martin La Plata, La Plata, Argentina, ⁴HIGA General San Martin La Plata, la plata, Argentina
Background/Purpose: Infections in patients with systemic necrotizing vasculitis represent one of the main causes of mortality. Risk factors of infection such as corticosteroid use, intensity…
Abstract Number: 18L • 2017 ACR/ARHP Annual Meeting
Rituximab As Re-Induction Therapy in Relapsing ANCA-Associated Vasculitis
Rona Smith¹, Rachel Jones², Ulrich Specks³, Carol A McAlear⁴, Kim Mynard², Simon Bond², David Jayne⁵ and Peter A. Merkel⁶, ¹Department of Medicine, University of Cambridge, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom, ³Mayo Clinic College of Medicine, Rochester, MN, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ⁶Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

Background/Purpose: RITAZAREM (ClinicalTrials.gov: NCT01697267) is an international, randomized, controlled trial comparing rituximab with azathioprine as maintenance therapy after induction of remission with rituximab and glucocorticoids…
Abstract Number: 814 • 2017 ACR/ARHP Annual Meeting
Clinical Presentation and Outcome of Orbital Mass in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides
Cécile-Audrey Durel¹, Arnaud Hot², Ludovic Trefond³, Olivier Aumaître⁴, Grégory Pugnet⁵, Maxime Samson⁶, Sébastien Abad⁷, Alexandre Belot⁸, Claire Blanchard-Delaunay⁹, Pascal Cathebras¹⁰, Pascal Cohen¹¹, Fleur Cohen¹², Vincent Cottin¹³, Bruno Crestani¹⁴, Stéphanie Dumonteil¹⁵, Claire de Moreuil¹⁶, Stéphane Durupt¹⁷, Jean-Gabriel Fuzibet¹⁸, Margaux Garzaro-regard¹⁹, Nicolas Girszyn²⁰, Bertrand Godeau²¹, Eric Hachulla²², Yvan Jamilloux²³, Patrick Jego²⁴, Estibaliz Lazaro²⁵, Thomas Le Gallou²⁶, Eric Liozon²⁷, Thierry Martin²⁸, Thomas Papo²⁹, Antoinette Perlat²⁶, Pascal Pillet³⁰, Karim Sacre³¹, Pascal Sève³², Loïc Guillevin for the French Vasculitis Study Group³³ and Benjamin Terrier¹¹, ¹Internal Medicine, Hôpital Edouard Herriot, lyon, France, ²Internal Medicine, Hopital Edouard Herriot, Lyon, France, ³Internal medicine, CHU Gabriel-Montpied, clermont-ferrand, France, ⁴CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ⁵Service de Médecine Interne, CHU de Toulouse, Toulouse, Toulouse, France, ⁶Dijon University Hospital, Dijon, France, ⁷Internal medicine, Hôpital Avicennes, avicennes, France, ⁸Pediatric Rheumatology, CHU lyon, Hospices Civils de Lyon, HFME, lyon, France, ⁹Internal Medicine, Centre Hospitalier, Niort, France, ¹⁰Internal Medicine, University Hospital St Etienne, St Etienne, France, ¹¹Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ¹²Department of Internal Medicine 2. Referal center for SLE/APS, Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹³Louis Pradel Hospital, Claude Bernard University Lyon 1, Lyon, France, ¹⁴Pneumologie A, Hôpital Bichat - Claude Bernard, Paris, France, ¹⁵Internal medicine, CHU de Limoges, Limoges, France, ¹⁶CHU de Brest, Brest, France, ¹⁷Department of Internal and Vascular Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ¹⁸Internal medicine, Hôpital l'Archet, Nice, France, ¹⁹Internal medicine, CHU de Nice, Nice, France, ²⁰CHU de Rouen, Rouen, France, ²¹Internal medicine, Hôpital Henri-Mondor, Créteil, France, ²²CHU Lille, Département de Médecine Interne et Immunologie Clinique, F-59000 Lille, France, Lille, France, ²³Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ²⁴Medecine Interne, CHU Rennes, Rennes, France, ²⁵service de médecine interne et maladies infectieuses, CHU de Bordeaux, Pessac, France, ²⁶Internal medicine, CHU de Rennes, Rennes, France, ²⁷Departement of Internal Medicine, Limoges University Hospital, Limoges, France, ²⁸Cnrs UPR9021, Department of Clinical Immunology and Internal Medicine, Strasbourg University Hospital, IBMC CNRS UPR9021, Strasbourg, France, ²⁹Paris Bichat, Paris, France, ³⁰Paediatrics, Hôpital Pellegrin, University Hospital of Bordeaux, Bordeaux, France, ³¹Department of Internal Medicine, Bichat Hospital, Paris, France, ³²Internal medicine, Internal medicine department, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Lyon, France, ³³Service de Médecine Interne, Centre de Référence Maladies Auto-Immunes et Auto-Inflammatoires Systémiques Rares, Hôpital Cochin, Paris, France
Background/Purpose: Orbital mass is a rare ophthalmologic manifestation of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) that remains a therapeutic challenge. This study aimed to describe…
Abstract Number: 1764 • 2017 ACR/ARHP Annual Meeting
Small RNA Sequencing Shows Differential Plasma Microrna Expression in Patients with ANCA-Associated Vasculitis: A Pilot Study
Kevin Byram¹, Joseph F. Solus¹, Quanhu Sheng¹, Yan Guo¹, C Michael Stein¹ and Michelle J. Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Rheumatology, Vanderbilt Medical Center, Nashville, TN
Background/Purpose: MicroRNAs (miRNAs) are small RNA molecules (~22 nucleotides) that participate in post-transcriptional gene regulation. miRNAs have potential both as biomarkers for diagnosis and prognosis…
Abstract Number: 2936 • 2017 ACR/ARHP Annual Meeting
B-Cell Depletion By Rituximab Affects the Distribution of Effector Th-Cell Subsets in Patients with ANCA Associated Vasculitis
Wayel H. Abdulahad¹, Ulrich Specks², Theo Bijma³, Deborah J. Phippard⁴, Fredrick Karnell⁵, Noha Lim⁵, John H. Stone⁶ and Cees G.M. Kallenberg¹, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Mayo Clinic College of Medicine, Rochester, MN, ³UMCG, Groningen, Netherlands, ⁴3 Bethesda Metro Center,, Suite 400, Bethesda, MD, ⁵Immune Tolerance Network, Bethesda, MD, ⁶Rheumatology Unit, Massachusetts General Hospital, Boston, MA
Background/Purpose: The current study is aimed to assess the effect of B-cell depletion on the distribution of effector T-cell subsets in AAV-patients. Alterations in CD4+…
Abstract Number: 893 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Belimumab in Combination with Azathioprine for Remission Maintenance in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: A Multicenter Randomized, Placebo-Controlled Study
David Jayne¹, Daniel Blockmans², Raashid Luqmani³, Beulah Ji⁴, Yulia Green⁵, Leanne Hall⁶, David Roth⁷ and Peter A. Merkel⁸, ¹Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ²General Internal Medicine, University Hospital Gasthuisberg, Leuven, Belgium, ³Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁴GSK Stockley Park, Uxbridge, United Kingdom, ⁵GSK Stockley Park, Stockley Park, United Kingdom, ⁶GSK Stevenage, Stevenage, United Kingdom, ⁷GSK Collegeville, Collegeville, PA, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, MN
Background/Purpose: GPA (Wegener’s) and MPA are organ- and life-threatening systemic vasculitides characterized by the presence of ANCA-associated vasculitis (AAV), implicating B cells in disease pathogenesis.…
Abstract Number: 1767 • 2017 ACR/ARHP Annual Meeting
The Effect on Health-Related Quality of Life of Treatment for Remission Maintenance in ANCA-Associated Vasculitis Beyond 18 Months
Gunnar Tomasson¹, Antoine G. Sreih², David Cuthbertson³, Simon Carette⁴, Nader A. Khalidi⁵, Curry L. Koening⁶, Carol A. Langford⁷, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Philip Seo¹¹, Ulrich Specks¹², Steven R. Ytterberg¹³ and Peter A. Merkel¹⁴, ¹University of Iceland, Faculty of Medicine, Reykjavik, IS, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, McMaster University, Hamilton, ON, Canada, ⁶Rheumatology, University of Utah, Salt Lake City, UT, ⁷Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Medicine, Johns Hopkins University, Baltimore, MD, ¹²Mayo Clinic College of Medicine, Rochester, MN, ¹³Rheumatology, Mayo Clinic, Rochester, MN, ¹⁴Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Standard management of ANCA-associated vasculitis (AAV) involves treatment with immunosuppressive agents for at least 18 months. Treatment beyond 18 months reduces the rates of…
Abstract Number: 895 • 2017 ACR/ARHP Annual Meeting
Temporal Trends in Incidence and Outcomes of End-Stage Renal Disease Due to Granulomatosis with Polyangiitis in the US from 1995-2014
Zachary S. Wallace¹, Yuqing Zhang², Leo Lu³, John H. Stone⁴ and Hyon K. Choi⁵, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Temporal Trends in Incidence and Outcomes of End-Stage Renal Disease due to Granulomatosis with Polyangiitis in the US from 1995-2014 Background/Purpose: Granulomatosis with polyangiitis (GPA)…
Abstract Number: 1768 • 2017 ACR/ARHP Annual Meeting
Cocaine and ANCA Associated Vasculitis-like Syndromes – a Case Series
Sujith Subesinghe¹, Sander van Leuven², Leena Yalakki³, Shirish Sangle (Joint First Author)³ and David P. D'Cruz³, ¹Rheumatology and Lupus, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom, ²Rheumatology, Radboud University, Nijmegen, Netherlands, ³Louise Coote Lupus Unit, Rheumatology and Lupus, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: Cocaine is a potent illicit stimulant and may trigger a ÔpseudovasculitisÕ mimicking idiopathic ANCA vasculitis. We describe the clinical and serological manifestations of patients…
Abstract Number: 896 • 2017 ACR/ARHP Annual Meeting
The Steroid Tapering in ANCA Vasculitis Evaluation Study (STAVE) 2: A Systematic Review and Meta-Analysis
Jennifer Rodrigues¹, David Collister¹, Amy Archer², Kim Cheema³, Paul Alexander⁴, Christian Pagnoux⁵, Lehana Thabane⁴, Peter A. Merkel⁶, David Jayne⁷ and Michael Walsh¹, ¹Nephrology, McMaster University, Hamilton, ON, Canada, ²Rheumatology, Northwestern University, Chicago, IL, ³Nephrology, University of Calgary, Calgary, AB, Canada, ⁴Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada, ⁵Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁶Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ⁷Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Relapses of ANCA-associated vasculitis (AAV) are associated with death, decreased renal function, and end-stage renal disease. Whether longer-term treatment with glucocorticoids (GC) reduces the…
Abstract Number: 1769 • 2017 ACR/ARHP Annual Meeting
Incidence, Predictors, and Outcome of Diffuse Alveolar Hemorrhage in Patients with MPO-ANCA Positive Microscopic Polyangiitis: A Multi-Center Retrospective Cohort Study
Takashi Kida, Shunya Kaneshita, Takuya Inoue, Amane Nakabayashi, Yuji Kukida, Kazuki Fujioka, Hidetake Nagahara, Makoto Wada, Takahiro Seno, Masataka Kohno and Yutaka Kawahito, Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan
Background/Purpose: In patients with microscopic polyangiitis (MPA), a variety of pulmonary lesions including diffuse alveolar hemorrhage (DAH), airways disease and interstitial lung disease (ILD) have…
Abstract Number: 1010 • 2017 ACR/ARHP Annual Meeting
Identification of Circulating Biomarkers of Disease Activity and Organ Involvement in ANCA-Associated Vasculitis By Targeted Proteomics
Jun Ishizaki¹, Ayako Takemori², Koichiro Suemori¹, Takuya Matsumoto¹, Yoko Akita¹, Masaki Yasukawa¹, Nobuaki Takemori² and Hitoshi Hasegawa¹, ¹Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ²Division of Proteomics Research, Proteo-Science Center, Ehime University, Ehime, Japan
Background/Purpose: Targeted proteomics, which involves quantitative analysis of targeted proteins using selected reaction monitoring (SRM) mass spectrometry, has emerged as a new methodology for discovery…
Abstract Number: 1770 • 2017 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitis (AAV) in Younger Vs Older Patients: Comparison of Clinical, Serologic and Outcome Differences and Their Implications for Management
Priya Chokshi¹, Olufemi Aina², Naveed Masani², Melissa Fazzari³, Elise Belilos¹, Kristina Belostocki¹, Gary Rosenblum¹, Tobin Abraham⁴, Daniil Shimonov⁴, Zinal Patel⁴ and Steven E. Carsons¹, ¹Rheumatology, NYU Winthrop Hospital, Mineola, NY, ²Nephrology, NYU Winthrop Hospital, Mineola, NY, ³Biostatistics, NYU Winthrop Hospital, Mineola, NY, ⁴Medicine, NYU Winthrop Hospital, Mineola, NY
Background/Purpose: ANCA-associated vasculitis (AAV) is a cause of multi-organ disease in all ages, but peaks at ages 65-74. Limited data is available on the characteristics…
Abstract Number: 1013 • 2017 ACR/ARHP Annual Meeting
HLA-Class II Associations with ANCA-Associated Vasculitis in the Japanese Population: Different Features from European Populations
Aya Kawasaki¹, Fumio Hirano², Ken-ei Sada³, Shigeto Kobayashi⁴, Hidehiro Yamada⁵, Hiroshi Furukawa¹, Kenji Nagasaka⁶, Takahiko Sugihara⁷, Kunihiro Yamagata⁸, Takayuki Sumida⁹, Shigeto Tohma¹⁰, Shoichi Ozaki⁵, Seiichi Matsuo¹¹, Hiroshi Hashimoto¹², Hirofumi Makino¹³, Yoshihiro Arimura¹⁴, Masayoshi Harigai¹⁵ and Naoyuki Tsuchiya¹, ¹Molecular and Genetic Epidemiology Laboratory, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ²Departments of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, ³Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Internal Medicine, Juntendo University Koshigaya Hospital, Koshigaya, Japan, ⁵Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ⁶Department of Rheumatology, Ome Municipal General Hospital, Ome, Japan, ⁷Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ⁸Department of Nephrology, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ⁹Department of Internal Medicine, University of Tsukuba, Faculty of Medicine, Tsukuba, Japan, ¹⁰Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ¹¹Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ¹²Juntendo University School of Medicine, Tokyo, Japan, ¹³Okayama University Hospital, Okayama, Japan, ¹⁴First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁵Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: HLA-class II region harbors the strongest genetic factors for ANCA-associated vasculitis (AAV), and differences in the genetic background of HLA-class II may partly explain…
Abstract Number: 1771 • 2017 ACR/ARHP Annual Meeting
Prevalence and Prognostic Relevance of Cardiovascular Involvement in ANCA-Associated Vasculitis: A Retrospective Cohort Study
Qin Huang¹, Hao Ren¹, Yaping Zhan², Shenyi Yu² and Min Yang¹, ¹Department of Rheumatology, Nanfang Hospital，Southern Medical University, Guangzhou, China, ²Department of rheumatology, Nanfang Hospital，Southern Medical University, Guangzhou, China
Background/Purpose: Cardiovascular involvement in ANCA-associated vasculitis (AAV) including microscopic polyangiitis (MPA), eosinophilic granulomatosis with polyangiitis (EGPA) and granulomatosis with polyangiitis (GPA), has long been regarded…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].